2024 annual financial data
Allogene Therapeutics 2024 Operating margin
Allogene Therapeutics 2024 operating margin with verified reported values.
Direct answer
Operating margin was -1,241,813.64%.
Operating income was -273,199,000 USD and net income was -257,590,000 USD.
Operating cash flow was -200,300,000 USD.
Get free Allogene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 22,000 USD
- Operating income
- -273,199,000 USD
- Net income
- -257,590,000 USD
- Operating cash flow
- -200,300,000 USD